000			03410nam a22004815i 4500
001			978-1-59745-169-7
003			DE-He213
005			20161121230840.0
007			cr nn 008mamaa
008			100301s2008 xxu| s |||| 0|eng d
020			_a9781597451697 _9978-1-59745-169-7
024	7		_a10.1007/978-1-59745-169-7 _2doi
050		4	_aRC261-271
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
082	0	4	_a614.5999 _223
245	1	0	_aCancer Proteomics _h[electronic resource] : _bFrom Bench to Bedside / _cedited by Sayed S. Daoud.
264		1	_aTotowa, NJ : _bHumana Press, _c2008.
300			_aXII, 264 p. 5 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aCancer Drug Discovery and Development
505	0		_aProteomics Technologies -- Current and Emerging Mass Spectrometry Instrumentation and Methods for Proteomic Analyses -- Cell Signaling Proteomics -- Integration of Genomics and Proteomics in Dissecting p53 Signaling -- Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy -- Tumor Proteomics -- Oncoproteomics for Personalized Management of Cancer -- Application of Serum and Tissue Proteomics to Understand and Detect Solid Tumors -- Insight on Renal Cell Carcinoma Proteome -- Proteomics in Lung Cancer -- Proteomic Strategies of Therapeutic Individualization and Target Discovery in Acute Myeloid Leukemia -- New Tumor Biomarkers -- Bioinformatics and Regulatory Aspects of Proteomics -- Annotating the Human Proteome -- Regulatory Issues in the Co-Development of Oncology Drugs and Proteomic Tests: An Overview.
520			_aOver the past 20 years or so, there have been tremendous advances in our understanding of how normal cells transform to cancer and the importance of signaling pathways in cancer initiation and progression. Therefore, proteomics technologies must be improved for more global analysis of protein content of cells, tissues and body fluids as well as the posttranslational modifications to allow for proper detections and validation. In Cancer Proteomics, the authors collectively provide the current status of proteomics in cancer therapy and offers the existing technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. Insightful to the reader with broad perspectives on topics related to the use of proteomic strategies in cancer therapy, Cancer Proteomics offers anticipated challenges that may arise from its application in daily practice.
650		0	_aMedicine.
650		0	_aCancer research.
650		0	_aOncology.
650		0	_aProteomics.
650	1	4	_aBiomedicine.
650	2	4	_aCancer Research.
650	2	4	_aProteomics.
650	2	4	_aOncology.
700	1		_aDaoud, Sayed S. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781588298584
830		0	_aCancer Drug Discovery and Development
856	4	0	_uhttp://dx.doi.org/10.1007/978-1-59745-169-7
912			_aZDB-2-SME
950			_aMedicine (Springer-11650)
999			_c504865 _d504865